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ORIGINAL ARTICLEMultiparametric Magnetic Resonance Imaging of
Prostate Cancer Bone Disease
Correlation With Bone Biopsy Histological and Molecular FeaturesRaquel Perez-Lopez, MD, PhD,*† Daniel Nava Rodrigues, MD,† Ines Figueiredo, BSc,†
Joaquin Mateo, MD, MSc,*† David J. Collins, BMIP,*† Dow-Mu Koh, MD, FRCR, MRCP,*†
Johann S. de Bono, MB, ChB, PhD,*† and Nina Tunariu, MD, FRCR, MRCP*†Objectives: The aim of this study was to correlate magnetic resonance imaging
(MRI) of castration-resistant prostate cancer (CRPC) bone metastases with histo-
logical and molecular features of bone metastases.
Materials and Methods: Forty-three bone marrow biopsies from 33 metastatic
CRPC (mCRPC) patients with multiparametric MRI and documented bone
metastases were evaluated. A second cohort included 10 CRPC patients with
no bone metastases. Associations of apparent diffusion coefficient (ADC),
normalized b900 diffusion-weighted imaging (nDWI) signal, and signal-weighted
fat fraction (swFF) with bone marrow biopsy histological parameters were
evaluated using Mann-Whitney U test and Spearman correlations. Univariate
and multivariate logistic regression models were analyzed.
Results: Median ADC and nDWI signal was significantly higher, and median
swFF was significantly lower, in bone metastases than nonmetastatic bone
(P < 0.001). In the metastatic cohort, 31 (72.1%) of 43 biopsies had detectable
cancer cells. Median ADC and swFF were significantly lower and median nDWI
signal was significantly higher in biopsies with tumor cells versus nondetectable
tumor cells (898 10−6 mm2/s vs 1617 10−6 mm2/s; 11.5% vs 62%; 5.3 vs 2.3,
respectively; P < 0.001). Tumor cellularity inversely correlated with ADC and
swFF, and positively correlated with nDWI signal (P < 0.001). In serial biopsies,
taken before and after treatment, changes in multiparametric MRI parameters
paralleled histological changes.
Conclusions:Multiparametric MRI provides valuable information about mCRPC
bone metastases. These data further clinically qualify DWI as a response bio-
marker in mCRPC.
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diffusion-weighted imaging, biopsies
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T herapeutic options for patients with metastatic castration-resistantprostate cancer (mCRPC) have increased over the last decade
Received for publication June 12, 2017; and accepted for publication, after revision,
July 29, 2017.
From the *The Institute of Cancer Research; and †The Royal Marsden NHS Founda-
tion Trust, London, United Kingdom.
Funding information: Prostate Cancer UK (PG14-016-TR2), Prostate Cancer Foundation
(20131017), Stand Up To Cancer (SU2C-AACR-DT0712), Movember Foundation
(Movember-Prostate Cancer UK Centre Grant CEO13-2-002), and Cancer Re-
search UK (C347/A18077 and CRUK C1060/A16464).
R.P.L. and D.N.R. are joint first authors.
Supplemental digital contents are available for this article. Direct URL citations appear
in the printed text and are provided in the HTML and PDF versions of this article
on the journal’s Web site (www.investigativeradiology.com).
Correspondence to: Nina Tunariu, MD, FRCR, MRCP, Radiology Consultant at The
Royal Marsden NHS Foundation Trust, Downs Road, SM2 5PT, London,
United Kingdom. E-mail: Nina.Tunariu@icr.ac.uk.
Copyright © 2017 The Author(s). Published byWolters Kluwer Health, Inc. This is an
open-access article distributed under the terms of the Creative CommonsAttribution-
Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permis-
sible to download and share the work provided it is properly cited. The work cannot
be changed in any way or used commercially without permission from the journal.
ISSN: 0020-9996/18/5302–0096
DOI: 10.1097/RLI.0000000000000415
96 www.investigativeradiology.comwith the approval of several agents improving overall survival.1–4 Yet,
as progression on these treatments inevitably ensues, mCRPC remains
a fatal condition. For optimal development of more precise therapeutic
strategies, there is a need for the clinical qualification of predictive bio-
markers, which requires acquisition of tumor material, and better re-
sponse biomarkers to guide therapeutic decisions.
Bone metastases are the most common (>80%) metastatic site in
advanced mCRPC; inmore than 40% of the patients, these represent the
sole site of metastatic spread.5 Although metastatic bone marrow biop-
sies have been successfully implemented in prior studies,6 acquiring
these samples remains difficult as bone marrow biopsies can yield spec-
imens with poor tumor content due to increased sclerosis or response
to previous therapies. Imaging that could increase the likelihood of
obtaining high-quality tumor samples remains a highly desirable goal.7
Furthermore, standardized imaging response criteria for bone metasta-
ses remain a major unmet medical need.8,9
Multiparametric (MP) magnetic resonance imaging (MRI) in-
cluding T1-weighted sequences, diffusion-weighted imaging (DWI),
and Dixon quantitative chemical shift imaging-derived fat fraction (FF)
allows the study of anatomical and functional features of bone marrow.
Diffusion-weighted imaging studies the random movement of water
molecules within a tissue and has high sensitivity and specificity for
the detection of bone metastases.10 Multiple studies have previously
shown a strong correlation between apparent diffusion coefficient
(ADC), the quantitative parameter derived from DWI, and tissue cellu-
larity in soft tissue tumors.11–17 In addition, several studies have shown
significant ADC differences between normal bone marrow and malig-
nancies in the bone.18–20 However, only limited data are available corre-
lating DWI parameters with cellularity and other histological features
in bone metastases.21,22 Translational studies correlating functional im-
aging and the underlying histology are critical for clinical qualification
of MP-MRI as a prognostic and response biomarker in prostate cancer
bone metastases.
Normal bone marrow contains both fat and water (yellow marrow
approximately 80% fat; red marrow approximately 40% fat).23 Malignant
cells displace the bone marrow fat cells causing a reduction in fat content;
conversely, successful therapies are associated with return of normal bone
marrow fat.24Dixon quantitative chemical shift imaging uses the difference
in resonance frequency betweenwater and fat to estimate FFof a tissue.23
We hypothesized that MP-MRI provided accurate in vivo in-
formation about bone metastases characteristics. We correlated
MRI quantitative parameters of mCRPC bone metastases within the bi-
opsy tract, including ADC, normalized b900 DWI (nDWI) signal inten-
sity, and signal-weighted fat fraction (swFF), with histological and
molecular bone biopsy features including tumor cell burden, immature
osteoid burden, fibrosis, proportion of fat, expression for the phosphatase
and tensin homolog (PTEN, a tumor suppressor gene frequently deleted
or mutated in prostate cancer resulting in lack of protein expression),
and Ki67 proliferation index. We also assessed the MP-MRI features
of normal bone marrow in a subgroup of patients with prostate cancer
and no evidence of bone metastases on multimodality imaging.Investigative Radiology • Volume 53, Number 2, February 2018
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This was a retrospective study conducted under Royal Marsden
Research Ethics Committee approval. Written informed consent was
obtained from all patients.
Patient Population
We reviewed all consecutive posterior iliac crest bonemarrow bi-
opsies and MP-MRI in mCRPC patients at The Royal Marsden Hospi-
tal (United Kingdom) performed between May 2012 and March 2016
as part of a prospective molecular characterization study.6 Study inclu-
sion criteria were (a) bone metastases in the posterior iliac crest, corre-
sponding to the area of the routine bone marrow biopsy, based on
computed tomography (CT), bone scan (BS), and MRI; (b) MP-MRI
within 12 weeks before the bone biopsy; and (c) presence of a visible
bone biopsy tract in the posterior iliac crest on a subsequent CT. Cases
were excluded if (a) bone biopsy did not include bone tissue or (b)
MP-MRI study had suboptimal DWI due to artifacts or was incomplete.
A second control cohort included 10 consecutive patients who
underwent MP-MRI but had no detectable bone metastases on a CT
and BS performed with 12 weeks of the MP-MRI and either on the
MP-MRI; no bone biopsies were obtained in this cohort for ethical
reasons. To be included in the control cohort, cases had to (1) have
a prior diagnosis of prostate cancer, (2) be under castration treat-
ment, and (3) have both a CT and a BS performed within 12 weeks
of the MP-MRI.
Clinical Data Collection
Data from patient records were collected into an anonymized da-
tabase; these included age, prior treatments, and laboratory parameters
at the time of the MRI. The presence of bone metastases was assessed
based onCTandBS performed at any time point before the bone biopsyTABLE 1. Population Characteristics of Patients With BoneMetastases an
Have Biopsies (n = 10)
Previous Treatments
Cohort With Bone
Biopsies (n = 4
Prostate radiotherapy 14 (32.6
Pelvic bone radiotherapy 19 (44.2
Abiraterone 36 (83.3
Enzalutamide 15 (34.9
Docetaxel 32 (74.4
Cabazitaxel 18 (41.9
Cabozantinib 3 (7.0%
Rad 223 5 (11.6
Bisphosphonates 10 (23.3
Clinical Characteristics Median (
PSA, ng/mL 345 (126–
CTC, cells per 7.5 mL of blood 18 (6–12
Hemoglobin, g/dL 112 (106–
Alkaline phosphatase, IU/L 164 (105–
Lactate dehydrogenase, IU/L 189 (165–
Bone Scan Index (%) Median (
Total biopsy cohort (n = 35) 5.6 (2.6–
Biopsy positive for tumor cells (n = 25) 5.6 (3.6–
Biopsy negative for tumor cells (n = 10) 5.5 (1.0–
CTC indicates circulating tumor cells; IQR, interquartile range; PSA, prostate spec
© 2017 Wolters Kluwer Health, Inc. All rights reserved.and MP-MRI performed within 12 weeks before the bone biopsy, in
all cases.
Histological and Molecular Parameters
Bone biopsies were decalcified in 14% EDTA and processed as
previously described.7 Sections were cut at 2 μm onto glass slides and
stained with hematoxylin and eosin. A pathologist (D.N.R.) blinded to
clinical and radiological data reviewed the biopsies. Tumor cellularity
was semiquantitatively scored into 4 tiers: 0 (no tumor cells), +1 (≤50
tumor cells), +2 (50–250 tumor cells), and +3 (≥250 tumor cells) by
section. Trabecular volume was semiquantitatively calculated as de-
scribed by Teman et al.25 Gross fibrosis and immature osteoid (woven
bone) content were semiquantitatively scored as follows: 0 (absent),
+1 (present in <1/3 of biopsy), +2 (≥1/3 to <2/3 of biopsy), and +3
(≥2/3 of biopsy). Fat content was defined as the area occupied by fat/
total biopsy area (100).PTEN and Ki67 were assessed by immunohis-
tochemistry as previously described.26 PTEN loss was defined as
H-score of 10 or lower.
MP-MRI Parameters
Multiparametric-MRI was performed on a 1.5 T MRI scanner
(Magnetom Avanto or Aera Siemens Healthcare, Erlangen, Germany),
using surface and body coils on patients positioned supine (Supplemental
Digital Content 1, Supplementary Table 1, http://links.lww.com/RLI/
A346). The DWI was performed in axial plane using b-values of 50
and 900 s/mm2. The swFF maps were calculated using an in-house
Osirix plug-in [FF = 100% Sfat/(Sfat + Swater), where S indicates signal
at every voxel location].
MRI and CT Analysis
Images were processed and analyzed with open-access imaging
assistant software (Osirix v5.6) by a single radiologist (R.P.L.), blindedd Biopsies (n = 43) and Those With No BoneMetastases Who Did Not
Metastases and
3), n (%)
Cohort With No Bone Metastases and
No Biopsies (n = 10), n (%)
%) 5 (50%)
%) 0 (0%)
%) 0 (0%)
%) 0 (0%)
%) 0 (0%)
%) 0 (0%)
) 0 (0%)
%) 0 (0%)
%) 0 (0%)
IQR) Median (IQR)
806) 23 (6–26)
1) —
125) 140 (132–155)
423) 56 (52–65)
239) 198 (162–200)
IQR)
10.2) —
9.2) —
10.1) —
ific antigen.
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TABLE 2. Histological and Molecular Characteristics of the Bone
Biopsies (n = 43)
Histological Characteristics n (%)
Osteoid
0 0 (0%)
1 9 (20.9%)
2 16 (37.2%)
3 18 (41.9%)
Fibrosis
0 4 (9.3%)
1 11 (25.6%)
2 8 (18.6%)
3 20 (46.5%)
Cellularity
0 12 (27.9%)
1 6 (13.9%)
2 9 (20.9%)
3 16 (37.2%)
Fat area Median (IQR)
% 25% (5%–50%)
Molecular Characteristics
PTEN expression (n = 22; unknown n = 21)
PTEN loss 8 (36.3%)
PTEN present 14 (66.6%)
Ki67 (n = 25; unknown n = 18) Median (IQR)
% 25% (10%–50%)
Perez-Lopez et al Investigative Radiology • Volume 53, Number 2, February 2018to pathology and molecular data. The biopsy tract was identified on a
postbiopsy axial CT; a 2-dimensional region of interest (ROI) delineat-
ing the biopsy tract was manually drawn. In the population with no bone
metastases, 2 bilateral ROIs delineating the posterior-superior iliac
crests at 1 level, representative for where standard bone marrow bio-
psies are usually performed, were manually drawn. The axial CT and
DWI sequences (b900, ADC, and FF maps) taken prebiopsy were
coregistered using the Osirix Insight Segmentation and Registration
Toolkit27,28; the ROIs were then transferred to the b900 images, ADC,
and swFF maps. To perform DWI signal normalization, ROI muscle
were delineated on b900 images within the gluteus maximus muscle
at the same side and level as the iliac crest bone marrow biopsy; nDWI
was defined as the ratio of biopsy tract b900 signal intensity to muscle
ROI b900 signal intensity. The following data were collated for each
ROI on MRI: nDWI signal intensity, ADC, and swFF.
If a CT was performed within 12 weeks of the bone biopsy,
coregistration of the CT prebiopsy and postbiopsy was performed;
CT density (Hounsfield units [HU]) of the ROI corresponding to
the biopsy tract in the prebiopsy CT scan images was recorded.
BS Analysis
If a whole-body BS had been performed within 12 weeks before
the bone biopsy, bone scan index (BSI) was calculated using an auto-
mated BSI scoring software (Exini Diagnostics, Lund, Sweden).29
Statistical Analysis
Descriptive statistics were used to summarize the baseline clini-
cal, histological, and molecular characteristics and imaging features.
Differences in MP-MRI and CT parameters between regions positive
and negative for tumor cells on bone biopsy were assessed using
Mann-Whitney U tests. Univariate analyses were performed using
logistic regression models. Variables with a statistically significant
association to bone biopsy positivity for tumor cells (P < 0.05) were in-
cluded in a multivariate logistic regression model. Correlations between
MP-MRI, histological, and molecular parameters were assessed using
Spearman correlation (r). The performance of the imaging biomarkers
was evaluated by receiver operating characteristic curve analysis and
linear discriminant analysis. Statistical analyses were performed with
Stata version 13 (StataCorp) and SPSS version 20 (IBM).
RESULTS
Patient and Bone Biopsy Characteristics
The flowchart of the study selection process is shown in Supple-
mental Digital Content 2, Supplementary Figure 1, http://links.lww.
com/RLI/A347. In the cohort of patients with bone metastases, 43
bone biopsies from 33 patients (all male; median age, 72 years; range,
48–84 years) were evaluable. Thirty-one (72.1%) of these 43 biopsies
were positive for tumor cells with 12 (27.9%) of 43 having no tumor
cells. In the cohort of patients with no detectable bone metastases, 10
CRPC patients were included (all male; median age, 69 years; range,
53–75 years). The population characteristics are summarized in
Table 1. The histological andmolecular characteristics of the bone biop-
sies are summarized in Table 2.
MP-MRI of Bone With or Without Prostate
Cancer Bone Metastases
The median ADC of bone metastases was significantly higher
than in nonmetastatic iliac crests: 993 10−6 mm2/s (interquartile range
[IQR], 872.5–1093.5  10−6 mm2/s) and 601.8  10−6 mm2/s (IQR,
545–667  10−6 mm2/s), respectively (P < 0.001). The median nDWI
signal was 4 (IQR, 2.6–6.7) in the bone metastases cohort and 1.6
(IQR, 1.4–2.7) in the cohort without bone metastases (P < 0.001).
The median swFF in bone metastases was 16% (IQR, 9%–45%),98 www.investigativeradiology.comsignificantly lower than in nonmetastatic bone, which was 63% (IQR,
60%–76%; P < 0.001).
Bone Metastases: MRI and Histological Parameters
The median ADC in the region of bone biopsies containing tu-
mor was 898 10−6 mm2/s (IQR, 816–1019 10−6 mm2/s), compared
with 1617  10−6 mm2/s (IQR, 1067–1787.5  10−6 mm2/s) in bone
with no visible tumor cells in the bone biopsy (P < 0.001). The median
nDWI signalwas significantly higher in bone biopsies containing tumor
cells (5.3 [IQR, 3.1–7.8]) compared with those with no detectable tu-
mor cells (2.3 [IQR, 2–3.3]; P < 0.001). Moreover, the median swFF
in positive bone biopsies was 11.45% (IQR, 8.5%–17%) compared
with 62% (IQR, 45%–82.9%) in bone biopsies not containing tumor
(P < 0.001) (Fig. 1; Supplemental Digital Content 3, Supplementary
Figure 2, http://links.lww.com/RLI/A348). Receiver operating
characteristic area under the curve values were 0.86 (95% confidence
interval [CI], 0.64–1.00) for median ADC, 0.87 (95% CI, 0.68–0.98)
for median nDWI signal, and 0.90 (95% CI, 0.74–1.00) for median
swFF (Supplemental Digital Content 4, Supplementary Figure
3, http://links.lww.com/RLI/A349).
We then evaluated whether the combination of these parameters
could improve their performance, using Linear Discriminant Analysis.
Because of the high correlation between median nDWI and median
ADC (P < 0.001), only median ADC and median swFF were consid-
ered in the model. The function combining median ADC and median
swFF was able to significantly discriminate biopsies with tumor from
biopsies without tumor and nonmetastatic bone (Wilks λ = 0.31;
P < 0.001). The function combining median ADC and median swFF
had a sensitivity of 80% and a specificity of 96% for the detection of
a positive bone marrow biopsy; 91.4% of the cases were correctly© 2017 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Box plots of the distribution of (A) median ADC, (B) median nDWI signal intensity, and (C) median swFF of the bone marrow in patients
with bone metastases and bone biopsy negative for tumor cells (green), bone metastases and bone biopsy positive for tumor cells (red), and no bone
metastases (blue).
TABLE 4. Univariate and Multivariate Logistic Regression Models
With Bone Marrow Positivity as the Dependent Variable
OR 95% CI P
Univariate logistic regression model
MRI Parameters
Investigative Radiology • Volume 53, Number 2, February 2018 MRI in Prostate Cancer Bone Metastasesclassified by the function (Supplemental Digital Content 5, Supplemen-
tary Table 2, http://links.lww.com/RLI/A350).
There was an inverse correlation between histological cellularity
burden as an ordinal variable and ADC (P < 0.001) and swFF (P < 0.001),
as well as a positive correlation with nDWI signal intensity (P < 0.001).
We also observed a positive correlation between the median swFF on
MP-MRI and percentage of histological fat content in the bone biopsies
(P < 0.001) (Table 3).
Immature osteoid and fibrosis in the bone biopsies were associ-
ated with positive biopsy results; in multivariate analysis, median ADC
remained independently associated with biopsy positivity for tumor
cells (P = 0.050) (Table 4).
In our series, median ADC of bone metastases did not correlate
with Ki67 proliferation index (r = 0.28, P = 0.180) or loss of PTEN ex-
pression (r = −0.34, P = 0.118).
Evaluating Bone Metastases by CT and BS
For 39 (90.7%) of 43 biopsies in the bone metastases cohort, a
CT scan performed within 12 weeks before the biopsy was also avail-
able. All the 10 patients in the cohort without bone metastases also
had a CT scan performed within 12 weeks of the MP-MRI.
Computed tomography density was significantly higher in
the presence of metastatic disease than in the bone with no metasta-
ses (median, 252 HU; IQR, 191–337.50 HU vs 67 HU; IQR 35–85
HU; P < 0.001).
In the metastatic cohort, 29 (74.4%) of the 39 patients with a CT
scan performed within 12 weeks of the bone biopsy had positive biop-
sies containing tumor cells. ThemedianHU onCTwas not significantly
different for bone metastases with positive biopsy compared with those
with negative biopsy without tumor cells present (median, 278 HUTABLE 3. Correlation Between MP-MRI and Histological Parameters
Generated From Bone Biopsy Analyses (Spearman r Correlation
Coefficient)
r P
Correlation with bone metastasis cellularity
Median ADC −0.57 <0.001
Median nDWI signal intensity 0.59 <0.001
Signal-weighted fat fraction −0.59 <0.001
Correlation with bone metastasis fat content
Signal-weighted fat fraction 0.60 <0.001
ADC indicates apparent diffusion coefficient; MP, multiparametric; MRI, mag-
netic resonance imaging; nDWI, normalized b900 diffusion-weighted imaging.
© 2017 Wolters Kluwer Health, Inc. All rights reserved.[IQR 139–348 HU] vs 241 HU [IQR 192–327 HU]; P = 0.966) (Sup-
plemental Digital Content 6, Supplementary Figure 4, http://links.
lww.com/RLI/A351).
Furthermore, in 35 (81.4%) of 43 biopsies, a BS was performed
within 12weeks (median, 2.7 weeks; IQR, 0.5–7.3 weeks) of the biopsy
with DICOM images allowing BSI calculation. Twenty-five (71.4%) of
these 35 biopsies were positive for tumor cells. The BSI was not signif-
icantly different in the group of patients with a positive biopsy com-
pared with those with negative biopsy (median, 5.6 [IQR, 3.6–9.2] vs
5.5 [IQR, 1.0–10.2], P = 0.812).
Features of Serial Bone Biopsies
In 3 cases, biopsies of the posterior-superior iliac crest were
taken at more than 1 time point, before and during treatment with differ-
ent anticancer therapies. Two of these cases were initially biopsied in
the presence of disease responding to therapy based on the PCWG2
criteria; in these posttreatment biopsies, median ADCs were high with
biopsy analyses identifying no tumor cells. At disease progression es-
tablished according to PCWG 2 criteria, however, median ADCs de-
creased and repeated bone biopsies detected tumor cells (Fig. 2).Median ADC 0.99 0.99–1.00 0.002
Median nDWI signal intensity 1.57 1.01–2.43 0.045
Signal-weighted fat fraction 0.96 0.94–0.99 0.008
Histological parameters
Osteoid score 3.14 1.19–8.31 0.021
Fibrosis score 4.02 1.68–9.61 0.002
Trabecular volume 1.02 0.98–1.06 0.276
Fat content 0.92 0.88–0.97 0.001
Multivariate logistic regression model
Median ADC 0.99 0.97–1.00 0.050
Osteoid score 6.34 0.04–1040.72 0.478
Fibrosis score 15.40 0.32–748.75 0.168
ADC indicates apparent diffusion coefficient; CI, confidence interval; MRI,
magnetic resonance imaging; nDWI, normalized b900 diffusion-weighted imag-
ing; OR, odds ratio.
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FIGURE 2. A 79-year-old man with widespread bone metastases, CT, MP-MRI (DWI, ADC, and FF), and bone biopsy histology during disease response
(A) and at disease progression (B) to abiraterone. A green ROI delineating the biopsy tract on CT imaging was transferred to registered MRI sequences
(DWI b900, ADC map, and FF map). The bone biopsies were decalcified, processed, and stained with hematoxylin and eosin. A black rectangle in 40
panel marks the region depicted in the200 panel. Median nDWI signal intensity in the area of the bone biopsy during disease response (A) was lower
than at disease progression (B) (2 vs 5), whereas median ADC values and swFF were higher during disease response (A) than at disease progression
(B) (1342 10−6 mm2/s vs 899 10−6 mm2/s; 20% vs 13%, respectively). In concordance withMRI parameters, despite both biopsies being targeted
to imagedbonemetastases, the bone biopsy at disease response (A)was negative for tumor cells and had 30% fat content, whereas at disease progression
(B), the bone biopsy was positive for tumor cells and had 5% fat content.
Perez-Lopez et al Investigative Radiology • Volume 53, Number 2, February 2018In the third patient with serial bone biopsies, a 74-year-old man
with mCRPC who had received previous radiotherapy to the pelvis be-
fore the first biopsy, the median ADC of the biopsied iliac crest was
similar at the 2 time points (1668  10−6 mm2/s and 1968  10−6
mm2/s, respectively), with both biopsies being negative for tumor cells.
These high ADC values would be consistent with maintained response
to previous radiotherapy.
DISCUSSION
In this study, we correlated MP-MRI parameters of bone metas-
tases, and of nonmalignant bone, with bone marrow biopsy histological100 www.investigativeradiology.comand molecular features in treated patients with CRPC. These findings
contribute to the clinical qualification of MP-MRI as a biomarker
of mCRPC.We have shown thatMP-MRI features including nDWI sig-
nal intensity, ADC values, and swFF successfully differentiate non-
metastatic bone from bone metastases in CRPC patients. The nDWI
signal intensity and ADC values in normal bone marrow in our popula-
tion were similar with those previously described18; these are closer to
the described values in yellow bone marrow than in red bone marrow,
in line with the high swFF observed in our study. These are consistent
with the advanced age of our population and chronic exposure to hor-
monal ablation for prostate cancer treatment. Low signal intensity and© 2017 Wolters Kluwer Health, Inc. All rights reserved.
Investigative Radiology • Volume 53, Number 2, February 2018 MRI in Prostate Cancer Bone Metastaseslow ADC values of yellow bone marrow are likely to be related to an
abundance of fat cells and reduced water proton density.
Within the bone metastases cohort, MP-MRI parameters pre-
dicted the presence and degree of cellularity of metastatic disease in
bone biopsies. In this heavily pretreated population, the absence of tu-
mor in negative biopsies likely reflects tumor cell kill after prior treat-
ments. We have shown a significant inverse correlation of ADC and
swFF, and a significant positive correlation of nDWI signal intensity
with bone metastasis tumor cellularity burden. This supports using
MP-MRI to guide bone biopsy acquisition in mCRPC for molecular
and histological studies. Our studies do indicate, however, that ADC
values and nDWI signal are also influenced by other histological find-
ings, such as the presence of osteoid and fibrosis in biopsies. Neverthe-
less, when controlling for fibrosis and osteoid in multivariate analysis,
median ADC was still independently correlated with tumor cellularity.
Furthermore, by using DWI b50 rather than b0 as our low b-value in
the DWI acquisition, we have reduced the influence of blood flow var-
iability on calculated ADC values. Lastly, in our study, MRI parameters
including ADC, nDWI and swFF were more informative of active ver-
sus nonactive bone metastases when compared with CT scan bone HU.
We acknowledge potential limitations of our study; first, our
pilot sample size is small, although still representing the largest series
presented to date of bone biopsy to MP-MRI correlative studies for this
disease. Furthermore, external validity of the performance of these bio-
markers by receiver operating characteristic curve and linear discrimi-
nant analysis is limited, due to the absence of a validation cohort.
Analyzing larger populations in prospective, multicenter validation
studies is now warranted for validation of these results. Second,
the retrospective nature of this studymay have led to some bias; patients
have been previously treated with different drugs including 10 patients
who received bisphosphonates; this may account for differences in the
MRI parameters, although, the number of patients was small for per-
forming subgroup analyses. Ideally, the MRI, CT, BS, and bone biopsy
should have been obtained simultaneously. However, we consider that
the 12-week maximum interval between the scans and biopsy is reason-
able considering the retrospective nature of this study and should not
have substantially impacted these results. Moreover, MRI, CT, and BS
assessments were always performed before the bone biopsy, avoiding
artifacts secondary to the biopsy procedure. Third, we estimated the
bone marrow fat as the swFF based on a 2-echoDixon sequence instead
of multiecho acquisition, which would allow a more reliable proton
density FF quantification.23,30 Fourth, histopathological analyses were
performed with core-needle biopsies and the small area of the drawn
ROIs on MRI and CT may not have been representative of tumor het-
erogeneity. Finally, further studies correlating MRI with histopathology
features from CT-guided bone metastases in areas outside the pelvis,
more prone to MRI artifacts, maybe of interest to validate these results
in bone metastases throughout the skeleton.
Overall, MP-MRI is a powerful noninvasive biomarker of the
histological features of bone metastases in prostate cancer. Multi-
parametric MRI differentiates normal bone marrow from bone metasta-
ses, and also bone metastases with detectable tumor cells from those
without tumor cells at biopsy, which can aid bone biopsy guidance. Fi-
nally, we have reported that changes inDWI parameters and histological
features parallel tumor progression and regression, probably as a result
of response to treatment. Overall, these findings, together with recent
published clinical studies,31,32 further support the clinical utility of
MP-MRI as a biomarker of bone metastases in mCRPC.ACKNOWLEDGMENTS
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